Since EGFRvIII-B16F10 cells, like their progenitor B16F10, express mD8-FAT1 on their surface (Figure 4A), we tested whether the combination of mD8-FAT1-OMVs and EGFRvIII-OMVs could further enhance the anti-tumor activity of EGFRvIII-OMVs immunization in mice challenged with EGFRvIII-B16F10. Here, FAT1 is linked to neoplasm.